Vodobatinib is under clinical development by Sun Pharma Advanced Research Company and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Vodobatinib’s likelihood of approval (LoA) and phase transition for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) took place on 02 Aug 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Vodobatinib Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Vodobatinib overview

Vodobatinib (SCO-088,SUNK-0706) is under development for treatment-resistant chronic myelogenous leukemia (CML) and Philadelphia chromosome positive acute lymphoblastic leukemia. The drug candidate is administered orally. It is a new chemical entity. SUNK-0706 targets Abl and Abl related kinases.

Sun Pharma Advanced Research Company overview

Sun Pharma Advanced Research Company (SPARC), a subsidiary of Shanghvi Finance Pvt Ltd, is a biopharmaceutical clinical research and development service provider. The company develops active pharmaceutical ingredients, formulations and drug delivery technologies for the treatment of cancer and inflammatory diseases. Its research category consists of therapeutic focus, delivery technologies, research programs and research and development pipeline. SPARC’s therapeutic focus comprises oncology, neurodegeneration, ophthalmology, dermatology and abuse-deterrent formulations. The company’s research and development pipeline includes levetiracetam ER, latanoprost BAK Free, salmeterol-fluticasone DPI, baclofen GRS, PICN, brimonidine OD, SDN – 021, SUN – K0706, SUN – 597 Topical, SUN – K0706, minocycline topical, SUN – K0954 and SDP – 037. SPARC is headquartered in Mumbai, Maharashtra, India.

Quick View Vodobatinib LOA Data

Report Segments
  • Innovator
Drug Name
  • Vodobatinib
Administration Pathway
  • Oral
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.